Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

AstraZeneca's Tagrisso gains FDA approval

(Sharecast News) - Drugmaker AstraZeneca traded higher early on Monday after revealing that a combination of its cancer drug Tagrisso with chemotherapy had gained US approval to treat a particular type of lung cancer. AstraZeneca said Tagrisso had been approved in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.

The FTSE 100-listed group stated the approval followed a priority review by the Food and Drug Administration and was based on the results from its FLAURA2 Phase III trial.

"Tagrisso with the addition of chemotherapy reduced the risk of disease progression or death by 38% compared to Tagrisso monotherapy which is the first-line global standard of care," said AZN. "Median progression-free survival by investigator assessment was 25.5 months for patients treated with Tagrisso plus chemotherapy, an 8.8-month improvement versus Tagrisso monotherapy (16.7 months)."

AstraZeneca added that as part of its "ongoing commitment to treating patients as early as possible in lung cancer", Tagrisso was also being investigated in the neoadjuvant setting in its NeoADAURA Phase III trial, with results expected later this year, and in the early-stage adjuvant resectable setting in the ADAURA2 Phase III trial.

As of 0920 GMT, AstraZeneca shares were up 3.05% at 10,402.0p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

Vector Capital reports robust year-end financial position
(Sharecast News) - Commercial lender Vector Capital reported continued growth in shareholders' equity while maintaining dividends and implementing prudent bad debt provision policies in its full-year results on Friday.
Quadrise posts progress with Utah partner Valkor
(Sharecast News) - Quadrise updated the market on its collaboration with Valkor Technologies in Utah on Friday, targeting the supply of low sulphur 'MSAR' and 'bioMSAR' to the marine and power sector.
Clean Power Hydrogen reports solid full-year progress
(Sharecast News) - UK-based green hydrogen technology company Clean Power Hydrogen (CPH2) reported solid progress towards the commercial rollout of its membrane-free electrolyser (MFE) technology in its final results on Friday, driven by a revamped engineering team.
Diesel generators arrive for Goldplat's South Africa operations
(Sharecast News) - South Africa and Ghana-focussed Goldplat announced the arrival of diesel generators at its South African operations on Friday.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.